Markets
In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on NeuBase Therapeutics (NBSE – Research Report), with a price target of $17.00. The company’s shares closed last Monday at $5.70, close to its 52-week low of $5.42.
According to TipRanks.com, Singh is a 5-star analyst with an average return of 15.4% and a 47.6% success rate. Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Catabasis Pharmaceuticals, and Vertex Pharmaceuticals.
NeuBase Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $17.33.
The company has a one-year high of $12.89 and a one-year low of $5.42. Currently, NeuBase Therapeutics has an average volume of 323.4K.
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2020
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
NeuBase Therapeutics CEO, Dietrich A Stephan, Ph D , to Present Accelerating the Genetic Revolution with a New Class of Synthetic Medicines at Tribe Public s Event on December 22, 2020
albuquerqueexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from albuquerqueexpress.com Daily Mail and Mail on Sunday newspapers.